

From: Maruna, Thomas
Sent: Tuesday, August 15, 2017 9:53 AM
To: 'Janice Castillo'; Dana Redhair (dredhair@Portola.com)
Cc: Chun, Haecin; McDowell, Erin; Cato, Dennis
(Dennis.Cato@fda.hhs.gov); Gildner, Jean; Ovanesov, Mikhail V.
Subject: 15-Aug-2017 Information Request (BIMO) - BLA 125586.0 -
Response
Due 29-Aug-2017

Portola Pharmaceuticals Inc.
Attention: Ms. Janice Castillo
August 15, 2017
Sent by email

Dear Ms. Castillo:

We are reviewing your August 4, 2017, biologics license application (BLA) resubmission for the following:

STN	Name of Biological Products
125586/0	Coagulation Factor Xa (Recombinant),
Inactivated	

We require the following information to be submitted to continue our review:

1. The tabulation data in your resubmission indicates that study subjects were enrolled for Protocol 14-505 from various study sites. Portola did not identify the clinical investigators who were associated those study sites. Please provide a complete listing of all study site information for Protocol 14-505; each study site should be identified with the following information:

- a. Clinical Investigator name
- b. Address
- c. Telephone number
- d. Study site number/other unique site identifier

Please also include this information in the IND.

2. Please provide the financial disclosure information for all clinical investigators and their subinvestigators who participated in the conduct of Protocol 14-505.

Please submit your responses as an amendment to this file by August 29, 2017. If you are unable to provide responses by August 29th, please propose an alternative date.

The action due date for these files is February 2, 2018.

If you have any questions, please contact Ms. Jean Gildner
(Jean.Gildner@fda.hhs.gov).

Very Respectfully,

Thomas J. Maruna, MSc, MLS(ASCP), CPH
Lieutenant, U.S. Public Health Service
Senior Regulatory Management Officer
Food and Drug Administration
Center for Biologics Evaluation and Research
Office of Blood Research and Review
10903 New Hampshire Ave.
Silver Spring, MD 20993
thomas.maruna@fda.hhs.gov
O: (240) 402-8454
www.usphs.gov

"THIS MESSAGE, INCLUDING ANY ATTACHMENTS, IS INTENDED ONLY FOR THE USE OF THE PARTY TO WHOM IT IS ADDRESSED AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL, AND PROTECTED FROM DISCLOSURE UNDER LAW. If you are not the addressee, or a person authorized to deliver the document to the addressee, you are hereby notified that any review, disclosure, dissemination, copying, or other action based on the content of this communication is not authorized. If you have received this document in error, please immediately notify the sender by e-mail or phone.

This email message is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorized review, use, disclosure or distribution is prohibited. If you are not the intended recipient, please contact the sender by reply email and destroy all copies of the original message. If you are the intended recipient, please be advised that the content of this message is subject to access, review and disclosure by the sender's Email System Administrator.